Kymera Investor Presentation Deck
KT-333 Achieved STAT3 Pathway Inhibition and Downregulation of
Inflammatory Biomarkers in Blood
Maximum % Decrease
in Plasma SAA (Mean ± SEM)
Maximum % Decrease
in Plasma CRP (Mean ± SEM)
-20-
-40-
-60-
-80-
-100
O
-20
-40-
-60-
-80-
-100-
00
D
C
to-
OO
O
SAA
O
C1 Week 1 C1 Week 2
CRP
O
O to
-●●
O O
C1 Week 1 C1 Week 2
DL1
DL2
DL3
DL1
DL2
DL3
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
% Change from C1D1 Predose
(Mean ± SEM)
●
●
●
●
300
200
100
-50
-75
KT-333
DL1
T
DL2
wal
DL3
1 2 3 4 5 6 7 8 9 10 11 12 29 30 31 32 33 34 35 36 37
Days in Study
SOCS3 % Change
100-
-50-
DL2
DL3
-75
-50
STAT3% Change
-87.5
Dose-dependent reduction in SOCS3 mRNA during Cycles 1 and 2
Correlation between changes in STAT3 protein and SOC3 mRNA
Additional gene expression changes measured in peripheral blood presently being analyzed
Reductions in plasma SAA and CRP, STAT3 regulated acute phase proteins
1
0
PAGE 48View entire presentation